TODAY'S EMAIL IS SPONSORED BY POLARTECHNICS, an Australian based BioTech Company that develops, manufactures and markets medical products for the detection of pre-cancer and cancer. The Company has developed unique, patented, cancer screening technologies. Polartechnics Chief Executive Officer, Ben Dillon, explained to the Australian Investor that “Polartechnics’ prime focus over the past 18 months has been the commercialisation of TruScreen, an alternative to the historic Pap smear. The uniqueness of TruScreen is that it provides women with immediate results at the point of care, thereby causing considerably less anxiety.” Polartechnics currently distributes its products and services through partnerships with local medical distributors in Asia, the Middle East and Europe. The current global distribution footprint has the potential to make TruScreen available to over 1 billion women. If you are interested in learning more about Polartechnics and its product portfolio click here: http://www.polartechnics.com.au
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)